CBD In Cosmetics: The State Of the European Union
Executive Summary
HBW Insight speaks to EU regulatory expert Amanda Isom of Bloom Regulatory Ltd about the current state of play in Europe’s CBD cosmetics market, reflecting on how it compares with the situation in US, and the EU market for CBD food supplements.
You may also be interested in...
UN Vote On Cannabis Controls Could Be Crucial To CBD’s Future In EU
Legal experts say the EU already prohibits cosmetic use of CBD sourced from hemp flowers, and it now appears that food supplement use could be held to the same standard. The World Health Organization has recommended changes to the half-century-old international treaty governing narcotic controls, which could help to resolve the situation, but there are reports of UN pushback.
EU CBD Market Under Threat With Narcotic Classification Favored
Leaning towards classifying CBD as a narcotic, the European Commission could dash hopes of a regulated EU market for dietary supplements containing the cannabinoid.
Over The Counter 2 Apr 2024: Analyzing The Spin-Out Trend In Consumer Health, With HBW’s Malcolm Spicer And Tom Gallen
In this episode, HBW Insight’s Europe and US editors bring their expertise to bear on the current the trend towards standalone OTC companies in global consumer health. We look at four major players: Haleon, which separated from GSK almost two years ago; Kenvue, soon to celebrate its first anniversary as a new company; Sanofi Consumer Healthcare, which is poised to split from its pharma parent; and Bayer, which has decided to buck the trend, holding on to its consumer health division. We discuss some of the advantages of becoming a standalone company, for example in leaning into a wider concept of self-care.